Preclinical studies have demonstrated that treatment with anti-IL-6 [23–28] or anti-IL-6R blocking antibodies [29] can increase the efficacy of immunotherapy, reduce tumor progression, and increase T-cell infiltration in several murine tumor models, including those of pancreatic cancer [23, 24]. The gene discussed is IL6R; the disease is pancreatic neoplasm.